Pediatric Nephrology

, Volume 19, Issue 2, pp 199–207 | Cite as

Renal replacement therapy for acute renal failure in children: European Guidelines

  • Vladimirs Strazdins
  • Alan R. WatsonEmail author
  • Ben Harvey
Open Access
Original Article


Acute renal failure (ARF) is uncommon in childhood and there is little consensus on the appropriate treatment modality when renal replacement therapy is required. Members of the European Pediatric Peritoneal Dialysis Working Group have produced the following guidelines in collaboration with nursing staff. Good practice requires early discussion of patients with ARF with pediatric nephrology staff and transfer for investigation and management in those with rapidly deteriorating renal function. Patients with ARF as part of multi-organ failure will be cared for in pediatric intensive care units where there should be access to pediatric nephrology support and advice. The choice of dialysis therapy will therefore depend upon the clinical circumstances, location of the patient, and expertise available. Peritoneal dialysis has generally been the preferred therapy for isolated failure of the kidney and is universally available. Intermittent hemodialysis is frequently used in renal units where nursing expertise is available and hemofiltration is increasingly employed in the intensive care situation. Practical guidelines for and the complications of each therapy are discussed.


Acute renal failure Peritoneal dialysis Hemofiltration Hemodialysis Guidelines 


Acute renal failure (ARF) is uncommon in childhood, but its incidence may be increasing and modalities of treatment changing with an increasing number of children being treated in the intensive care unit (ICU) with multi-organ failure. Traditionally children with ARF with renal involvement were only treated with peritoneal dialysis, but extracorporeal techniques are being increasingly used in ICUs.

Members of the European Pediatric Dialysis Working Group reviewed all modalities of renal replacement therapy for ARF in children and developed the following guidelines in collaboration with nursing staff during three meetings and extensive e-mail discussion. There are no randomized trials of renal replacement treatment in children with ARF. The guidelines are based upon published reports and consensus opinion to emphasize good practice.

ARF is recognized when renal excretory function declines rapidly. Rising values of plasma urea and creatinine are usually accompanied by oliguria (<1 ml/kg per hour), but occasionally patients may be polyuric. The cause of ARF may be pre-renal, intrinsic, or post-renal (obstructive) problems, and causes differ between neonates and older children [1, 2, 3].

The incidence of ARF in children is hard to define, as often renal insufficiency in the newborn and on ICUs is conservatively managed by ICU staff. Outside the neonatal period, ARF is an uncommon condition accounting for 8 referrals per million population per year to one regional pediatric nephrology unit in the United Kingdom [4].

ARF may occur as isolated failure of the kidneys alone, with other organ systems functioning normally, or in association with multiple organ failure. The mortality of the latter group is considerably higher, especially with the growth in pediatric intensive care. For example, the mortality in neonates and infants is 51% after cardiac surgery for congenital heart defects [4], but only 3%–6% for children with intrinsic renal disease such as hemolytic uremic syndrome (HUS) in developed countries [5, 6].

The case mix in different units treating ARF, and hence mortality and morbidity rates, will therefore vary according to local clinical activity and resources [7, 8]. Many pediatric renal units will be close to pediatric ICUs (PICUs) in hospitals that may offer cardiac surgery, liver transplantation, and specialist treatment for metabolic disorders, oncology patients, etc. [6]. Other renal units may be in hospitals that do not have a PICU on site and conversely there may be hospitals offering pediatric intensive care with no specialist pediatric nephrology service.


All children with ARF require discussion with a pediatric nephrologist. Early transfer for investigation and management is essential in those with rapidly deteriorating renal function or in those with hemodynamic or biochemical disturbances (good practice) [9].

All children with ARF as part of multi-organ failure require transfer to a designated regional pediatric ICU where there should be access to pediatric nephrology advice and support (good practice).


Since there are few comprehensive regional pediatric nephrology centers the distances that families may have to travel can be considerable. Children with acute renal impairment may be managed in local hospitals, but it is essential that early referral is made, especially if children have evidence of rapidly deteriorating renal function and require an urgent histological diagnosis to determine if immunosuppressive therapy or other treatment is required. Indications for referral include oligoanuria, especially if associated with fluid overload, hypertension, hyperkalemia, hyponatremia, acidosis, or the need for blood transfusion. Dialysis is often accompanied by early nutritional support and pediatric nephrology units should be equipped to provide the necessary medical and nursing expertise, combined with dietetic and psychosocial support. The latter support is also important if the child is managed conservatively.

Neonates and premature infants with ARF require transfer to a tertiary neonatal unit with pediatric nephrology team expertise. Patients with ARF and multi-organ failure require prompt transfer to a designated regional PICU.

The choice of dialysis therapy for ARF depends upon the clinical circumstances, patient location, and expertise available. Peritoneal dialysis (PD) has generally been considered the preferred therapy if there is isolated failure of the kidneys, such as HUS. It is regarded as a simpler technique that is universally available. However, hemofiltration (HF) and hemodiafiltration (HDF) are increasing in popularity in PICUs where the facilities to perform hemodialysis (HD) may not be available. HD may be the preferred mode of treatment in more-stable patients with adequate vascular access treated on renal units where specialist nurses are available.

Although extracorporeal techniques such as continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodiafiltration (CVVHDF) are used quite frequently in adult ICUs, there is still limited expertise in many PICUs. Such techniques are very dependent on technology and are more costly than PD [10]. They are also dependent upon the availability of appropriate nursing expertise [11]. Such expertise can be developed and maintained in units remote from the pediatric nephrology center by an outreach service using a renal critical care nurse educator [12].


There is no evidence for the optimum level of renal function for starting renal replacement therapy nor for the optimum dialysis modality. Advantages and disadvantages are listed in Table 1. Consideration should be given to establishing national and international databases to collect these data along with patient outcomes [6, 13].
Table 1

Advantages and disadvantages of various modalities of renal replacement therapy for acute renal failure (CVVH continuous venovenous hemofiltration, CVVHDF continuous venovenous hemodiafiltration)



Use in hypotension


Volume control


Peritoneal dialysis






Intermittent hemodialysis


















Choice of therapy

Acute PD

The main advantage of PD is that it is continuous therapy that requires neither anticoagulation nor vascular access, and the technique can be used in hemodynamically unstable patients [14]. Acute PD can be performed in units with no HD expertise and is effective in children of all ages, including neonates [15, 16, 17, 18]. PD has been used in treating acute pancreatitis, tumor lysis syndrome, intoxications, metabolic diseases, and other pathological conditions in children [19, 20, 21, 22]. The choice of PD as therapy has always to be individualized, balancing advantages against disadvantages.

Limitations in the use of PD

Inborn areas of metabolism in the newborn period lead to acute accumulation of neurotoxic metabolites that can be better removed using techniques such as CVVHDF [23, 24]. The latter technique requires good vascular access, which can still be a major problem in small children [25]. Newborns with respiratory diseases, even if on ventilatory treatment, can be treated with PD provided that the fill and exchange volumes are adapted to the clinical situation. However, caution is necessary in neonates with necrotizing enterocolitis and older children with suspected bowel perforation [26].

Preparation for PD

Dialysis is only possible if the access provides free flow in and out of the abdomen. The choice is between catheters inserted at the bedside under sedation or the placement of a chronic PD catheter by a pediatric surgeon in the operating theater, or exceptionally at the bedside in the ICU.

The rigid Trocath catheter with a stylet has largely disappeared and surgically placed Tenckhoff catheters are reported to have fewer complications [27, 28, 29]. However, small catheters for percutaneous placement using a Seldinger technique are invaluable in providing acute PD rapidly, especially in the neonatal PICU [13, 30].

Blockage by the omentum is always a risk with PD catheters. If the catheter is to be placed surgically then consideration should be given to partial omentectomy [31].

In patients who are having a PD catheter inserted under general anesthetic a cephalosporin antibiotic (20 mg/kg) should be given as a single intravenous dose up to 1 h prior to implantation of the catheter [32]. Any subsequent accidental contamination should result in the use of prophylactic antibiotics, e.g., cefuroxime 125 mg/l in the dialysate for 48 h.

For catheters that are inserted percutaneously, prophylactic antibiotics, e.g., cefuroxime 125 mg/l, should be added to the dialysis fluid unless the patient is on systemic treatment.

Heparin, 500 units/l, should be prescribed to prevent catheter blockage with fibrin. This is generally maintained for the first 48 h, and longer if the PD fluid remains slightly bloodstained [33, 34].

PD prescription

This needs to be individualized according to patient size and condition. Automated PD machines are the preferred method for delivering the individualized dialysis prescription and accurately measuring ultrafiltration [30]. Such machines are now available that can deliver dialysis volumes accurately down to 60 ml with 10-ml increments. Although such machines now have improved accuracy of ultrafiltration measurements, the dead space of the tubing can reduce dialysis efficiency. A manual PD set can be used, using burettes that can accurately measure inflow and outflow, with the PD fluid warmed appropriately [35]. With manual sets, attempts should be made to maintain a closed drainage system, which can help reduce the frequency of peritoneal contamination [36]. Such manual PD sets are commercially available for neonatal patients.

Choice of dialysis solution

The choice of dialysis solution will depend upon the weight, blood pressure, and hydration status of the child, bearing in mind the need to create nutritional space as part of the management strategy [37].

The general principle is to commence with the lowest concentration of glucose solution possible (1.36%), with stepwise increments. Care is needed if 3.86% glucose solution is required as (1) rapid ultrafiltration can occur (especially in infants) and (2) hyperglycemia may develop (especially in septic and multi-organ failure patients) leading to hyperosmolarity and loss of effective ultrafiltration.

Icodextrine solutions need a longer dwell time to obtain significant ultrafiltration and so are rarely indicated in ARF. Lactate-containing dialysis solutions are likely to be replaced by bicarbonate solutions, which are being evaluated in chronic PD. The routine use of bicarbonate solutions should be considered in neonates or in patients with reduced lactate metabolism or with lactic acidosis [38, 39].

Practical points

Patients should be connected and automated PD or manual cycles started immediately after catheter implantation. Heparin (500 units/l) should be added to the dialysis fluid to prevent fibrin deposition and to improve peritoneal solute permeability [33, 34], but it can be absorbed and care is needed in patients with coagulation disorders.

Dialysis fill volumes of 10–20 ml/kg (300–600 ml/m2) should be used initially, depending on the body size and cycle in and out, until the dialysate becomes clear.

A PD program with 1-h dwells should be used during the first 24 h. Shorter cycles can be considered initially if hyperkalemia needs urgent treatment.

The program should be adjusted with increasing dwell times and cycle fill volume (if no leakage problems) until the desired fill volume (800–1,200 ml/m2) is achieved, with adequate ultrafiltration and biochemical control [40].

High intraperitoneal pressure (IPP) can be a problem in the first 2–3 days after surgical catheter insertion. The measurement of IPP may limit the risk of leakage when the fill volumes are being increased and allow optimized pain management, but is not yet in routine use [41].

Inflow/outflow pain on PD usually diminishes with time. Tidal dialysis is an alternative [42] and bicarbonate dialysis should be considered [43].

The amount of ultrafiltration that is prescribed will partly depend upon the volume of oral, nasogastric, or total parenteral nutrition that is required, combined with fluid for drugs. Ultrafiltration may not be enough without the use of 2.27% or 3.86% glucose solutions.

The clinical, biochemical, and nutritional status of the patient should be assessed regularly in conjunction with an experienced renal dietitian [44]. Optimal nutrition is necessary to avoid a catabolic state and associated production of blood urea nitrogen and uremic products.


Patients with ARF need constant assessment while on PD, and adequacy should be judged in terms of clinical status, ultrafiltration achieved, and biochemical parameters, particularly urea, creatinine, and bicarbonate levels [40]. Although a link between the dialysis dose and the outcome of adult patients in ARF has been established [45], there are no guidelines as to what constitutes adequate PD in a child with ARF. The aim is to deliver maximum clearance to compensate for the catabolic stress.

Complications of acute PD

Leakages can be a difficult problem and are mostly due to a leakage around the catheter. The incidence can be reduced by proper surgical technique when using a Tenkhoff catheter [46] or resuturing around a percutaneous catheter. Fibrin glue injected into the catheter tunnel is a technique under evaluation [47].

Poor drainage due to mechanical blockage or catheter migration is all too common. Flushing the catheter and preventing fibrin accumulation by increasing the heparin dosage and/or urokinase is suggested initially [48]. A plain abdominal X-ray is rarely justified, as repeated poor drainage will require catheter relocation. If available, a laparoscopic technique may be used to correct poor drainage or replace the malfunctioning catheter [49].

Hernias can be a problem in neonates and infants, particularly males. They do not usually require interruption of PD and can be repaired electively by laparoscopic or direct measures when the child’s clinical condition has improved or stabilized.

Peritonitis remains a constant threat, especially if there has been a lot of manipulation of the catheter. The standard features of cloudy PD fluid require urgent attention [50].

Continuous extracorporeal techniques

Continuous arteriovenous hemofiltration (CAVH) has largely been replaced by pumped CVVH and CVVHDF, particularly in ICUs [51]. Such continuous renal replacement therapies (CRRT) have expanded the possible role of blood purification in the management of critically ill patients. However, there is a lack of randomized trials in patients with sepsis, and a recent analysis failed to show a benefit for hemofiltration [52]. Studies in adult ICU patients have shown a lower mortality in patients treated with CRRT compared with intermittent HD. However, a recent meta-analysis of studies before 1996 concluded that the evidence was insufficient to draw strong conclusions regarding the mode of renal replacement therapy for ARF in the critically ill [53]. A recent randomized trial in adult ICU patients showed a significant survival advantage when the intensity of ultrafiltration was increased [54].

Practical guidelines for prescription

Since the concentration of solutes in the filtrate is the same as in the plasma, biochemistry is controlled by removing large volumes of filtrate and replacing it with electrolyte-containing fluid (HF replacement fluid). As most solutes are distributed within the extracellular and intracellular fluid compartments (total body water), the exchange volume of filtration necessary to control biochemistry relates to total body water. Clinical experience has shown that a turnover of approximately 50% of body weight in 24 h is usually adequate for CVVH.

The extracorporeal circuit requires good central venous access, usually via a dual-lumen catheter, to allow the high blood flows necessary to prevent clotting in the hemofilter. Suggested catheter sizes in French gauge (FG) are:

Patient size (kg)

Vascular access


6.5-FG dual-lumen (10 cm)


8-FG dual-lumen (15 cm)


10.8-FG or larger dual-lumen (20 cm)

For neonates a 5-FG dual-lumen catheter may be adequate, and access can be obtained via the umbilical vein [55]. A single-lumen catheter using a “single needle” for CVVHD in very low birth weight infants has also been described [56], but this method may be compromised by high recirculation rates with most available systems. However, the smaller the access the greater the problems [57]. It is possible to consider placing two small single-lumen catheters in different central veins.

A low blood flow rate, high hematocrit, and high plasma protein concentration will limit the rate at which filtration can occur and solutes (particularly of higher molecular weight) are removed. For a given blood flow rate, pre-dilution results in higher clearance of solutes than does post-dilution [58], but at the expense of greater use of replacement fluid (approximately 20%–50% more). Pre-dilution has the potential for extending filter life.

As with HD, the blood volume in the extracorporeal circuit should be less than 10% of the patient’s circulatory volume. Blood flows of 6–9 ml/kg per min or 8% of circulating blood volume prevents excessive hemoconcentration in the filter. Automated machines with appropriate accuracy for children are recommended for delivering the CRRT prescription safely [59], and have replaced pump-assisted hemofiltration using volumetric pumps [60].

To achieve a 50% exchange of total body water in 24 h, an appropriate filter should be selected with a surface area of no more than the surface area of the patient. Suggested maximum filtration rates are:

Patient size (kg)

Maximum filtration rate (ml/h)







Under post-dilution conditions, the filtration rate should never exceed one-third of the blood flow.

Several filter materials are now available. Synthetic membranes have replaced cellulose acetate, as they are more biocompatible, causing less complement reaction and anticoagulation needs. The synthetic polysuphone membranes are also thought to aid convective clearance of solutes through solute drag [61].

A variety of replacement fluids are available such as lactate, bicarbonate, and buffer-free solutions. Bicarbonate or buffer-free solutions should be used in young infants and those intolerant of lactate. If a commercially available bicarbonate solution were freely available, then this would be the solution of choice. Careful monitoring of electrolytes, glucose, and phosphate is essential, as the constituents vary between the solutions.


The goals of anticoagulation are to prevent clotting of the circuit and maintain adequate clearances with minimal risk to the patient. Heparin is the standard anticoagulant in Europe, but the choice of dosage will depend upon the patient’s coagulation status, adequacy of blood flow, and blood viscosity. In most patients, heparin should be administered as an initial bolus (maximum 50 units/kg) at the time of connection to the extracorporeal circuit, followed by a continuous infusion of 0–30 units/kg per hour. The activated clotting time (ACT) or whole blood activated partial thromboplastin time (aPPT) are usually used to monitor treatment. The optimal ACT during hemofiltration is 120–180 s. The aPPT should be between 1.2 and 1.5 times the respective baseline value. Some patients can be treated without heparin in the circuit [6].

In those patients who are severely thrombocytopenic or where there is suspected heparin-induced thrombocytopenia, alternative treatment with prostaglandin infusions or recombinant hirudin [62], a direct thrombin inhibitor, can be considered [63].

Regional anticoagulation with citrate has been favored by some centers [64, 65]. Sodium citrate chelates ionized calcium necessary for the coagulation cascade and systemic anticoagulation is avoided by infusing calcium through a separate central line. The disadvantages include the possibility of various acidbase and electrolyte disturbances, including hypernatremia, hypocalcemia, and metabolic alkalosis.

Adjustment of the prescription

Any formula for the prescription of HF is at best an approximation or starting point, as the needs will be determined by many unmeasured variables, such as the rate of solute production, nutritional intake, and the actual volumes of the extracellular fluid and intracellular fluid compartments.

If only fluid removal is required, then relatively low rates of filtration are needed, often referred to as slow continuous ultrafiltration (SCUF). There will be negligible solute removal under these circumstances.

Correction of “uremia” and electrolyte disturbance requires the turnover of large volumes per kilogram of fluid, typically of the order of 50% of body weight per day for post-dilution and 75% for pre-dilution (approximately 20–30 ml/kg per hour).

In catabolic patients, the clearances achieved with standard CVVH may not be sufficient. Solute removal may be increased by attempting “high-volume exchange,” but this may be limited by the practical problems of pediatric patients with limitations of vascular access and hemoconcentration in the filter. In these cases, small solute clearances can be maximized by establishing diffusive mass transport via a dialysis circuit. This can be performed with CVVHDF or without an additional major ultrafiltration component (CVVHD). CVVHDF latter technique requires an additional pump to achieve separate control of the dialysate in- and outflow and of the replacement fluid flow. CVVH substitution fluid bags can be used as dialysis fluid. Dialysis fluid flow should be 2–3 times the blood flow if maximal efficacy is desired. This setting requires frequent manual bag exchanges and continuous supervision of the system. For practical purposes, the HD component can be added for several hours per day to a CVVH regimen.

CVVHD has recently been recommended as the method of choice for the treatment of inborn errors of metabolism, since it supplies maximal clearance of ammonium and other neurotoxic metabolites. When CVVHD is unavailable, large volume turnover of body water with CVVH will provide the next best therapy. Rates of up to 100 ml/kg per hour have been reported [66]. If possible, the blood pump speed also needs to be increased.

When high turnover and blood flow rates are in use, patients should be carefully monitored for hypothermia, hypokalemia, and circulatory failure. Hypothermia may need to be treated with an external warming blanket and hypokalemia will require replacement. Blood flow should not be increased if the patient develops cardiovascular instability.

CVVH and extracorporeal membrane oxygenation

In the authors′ experience, the best results are achieved when pre-diluted fully automated CVVH is used, attached to the venous (outflow from patient) side of the extracorporeal membrane oxygenation (ECMO) circuit. This appears to reduce problems of shunting blood around the oxygenator and overcomes the problems of the increased hematocrit that may be associated with ECMO. It also reduces the complications of excessive fluid and solute clearances, with a free flow when systemic hemofilters are used in line with the ECMO circuit. When using CVVH in the suggested configuration, the “pigtails” provide access with very little resistance, causing the arterial and venous pressure alarms to activate and shut down the circuit. Therefore, three-way taps are used to create more resistance to flow into and out of the CVVH circuit. When treating neonatal patients, the ECMO circuit increases the extracorporeal blood volume very significantly. Therefore, the blood pump speed should be calculated taking into account the patient’s blood volume and the priming volume of the ECMO circuit.

Complications of continuous extracorporeal techniques

Complications of continuous extracorporeal techniques are described in reference [67].


Hemofiltration is most commonly used in sick septic children, many of whom will be on pressor therapy. Indeed, the need for pressor agents gives a poorer prognosis [6]. Care should have been taken to minimize the amount of blood in the extracorporeal circuit and blood priming of the HF circuit may be necessary at the outset. Fluid removal is obviously adjusted according to the patient’s clinical state during the treatment.

Clotting of the filter and lines

This is one of the commonest complications and again is related to the patient’s changing clinical status and problems with anticoagulation. This complication occurred in 24% of 89 patients treated with CVVH in a 2-year local audit (B. Harvey, unpublished observations).

Other potential complications of bleeding, anticoagulation toxicity, and infections appear to be minimal. Air embolism is a rare but preventable complication of extracorporeal circuits, and is greatly reduced with the proper use of automated machinery.

Intermittent HD

The advantages and limitations of intermittent HD are described in reference [68].


The main advantage of HD is the relatively rapid removal of uremic toxins and ultrafiltration of fluid. This makes the technique well suited for acute situations.


HD is not a continuous therapy and it requires good vascular access as with HF. A purified water supply is also required, as well as anticoagulation, which should always be minimized. The technique might not be applicable for hemodynamically unstable patients. Often the major limiting factor is the availability of expert nursing staff [69], especially in the ICU [70].

Practical guidelines for prescription

HD is only possible with good vascular access provided either by a double-lumen HD catheter or a single-lumen catheter of sufficient diameter to achieve flows for single-needle dialysis. Catheter lengths vary from 5 cm for neonates to 20 cm for large adolescents.

Bloodline choice depends on the priming (extracorporeal) volume, which traditionally has not exceeded 10% of the blood volume (approximately 80 ml/kg).

Dialyzer choice depends on the priming volume and maximum flow rate, with a surface area that should not exceed the child’s surface area and with a urea clearance between 3 and 5 ml/kg per min. There is no evidence for dialyzer choice in pediatric practice, but meta-analysis in adult patients with ARF suggested synthetic membranes conferred a significant survival advantage over cellulose-based membranes, but with no similar benefit for recovery of renal function [71].

Bloodline priming is usually performed with isotonic saline. Small babies, anemic patients, and those in an unstable cardiocirculatory condition, require priming with albumin or blood.

HD catheter care

After the session the catheter should be flushed with isotonic saline and filled with undiluted heparin (1,000 IU/ml), with volumes according to manufacturer’s recommendations (usually marked on the catheter itself).

HD prescription

The first session should not exceed 2–3 h, but the standard time is usually 4 h. Longer sessions are advisable to avoid too-rapid ultrafiltration and disequilibrium syndrome.

All children should be dialyzed using volume-controlled machines and with bicarbonate dialysate.

The blood pump rate is usually 6–8 ml/kg per min, but depends upon the catheter and patient size [69].

The ultrafiltration target should not exceed 0.2 ml/kg per min for acute patients who should be carefully monitored for hypovolemia and hypotension. Sodium profiling is rarely used in pediatric HD practice. Anticoagulation is usually with heparin (50–100 IU/kg per session including initial bolus). Reinfusion is usually performed with isotonic saline.

Complications occurring during acute HD

For hypotension, the ultrafiltration should be switched off and isotonic saline infused into the venous line until the blood pressure normalizes; additional 20% albumin 5 ml/kg might be helpful.

Hypertension is treated according to standard hypertension protocols available elsewhere [72].

Disequilibrium syndrome is now a rare event with adequate control of ultrafiltration and stepwise reduction of uremic toxins.

Hypoglycemia should not occur with the use of glucose-containing dialysis fluid.

In cases of anemia transfusions are avoided unless patient symptomatic. Erythropoietin may be given intravenously at the end of dialysis (50–200 IU/kg) to maintain hemoglobin levels.


The clearance of drugs on HD or during CRRT needs to be considered. Reference should be made to standard texts [73, 74].



We thank Baxter Healthcare for financial support towards the meetings of the group and Judith Hayes for help with the manuscript.


  1. 1.
    Fitzpatrick MM, Kerr SA, Bradbury MG (2003) Acute renal failure. In: Webb N, Postlethwaite R (eds) Clinical paediatric nephrology, 3rd edn. Oxford University Press, Oxford, pp 405–425Google Scholar
  2. 2.
    Watson AR (2003) Renal disease in the neonate. In: McIntosh N, Helms PJ, Smyth RL (eds) Forfar and Arneil’s textbook of paediatrics, 6th edn. Churchill Livingstone, Edinburgh, pp 197–392Google Scholar
  3. 3.
    Flynn JT (2002) Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 17:61–69CrossRefPubMedGoogle Scholar
  4. 4.
    Moghal NE, Brocklebank JT, Meadow SR (1988) A review of acute renal failure in children: incidence, etiology and outcome. Clin Nephrol 49:91–95Google Scholar
  5. 5.
    Kaplan BS, Meyers KE, Schulman SL (1998) The pathogenesis and treatment of hemolytic uraemic syndrome. J Am Soc Nephrol 10:1126–1133Google Scholar
  6. 6.
    Bunchman TE, McBryde KD, Mottes TE, Gardner JJ, Maxvold NJ, Brophy PD (2001) Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 16:1067–1071CrossRefPubMedGoogle Scholar
  7. 7.
    Arora P, Kher V, Rai PK, Singhal MK, Galati S, Gupta A (1997) Prognosis of acute renal failure in children: a multivariate analysis. Pediatr Nephrol 11:153–155PubMedGoogle Scholar
  8. 8.
    Flynn JT (1998) Causes, management approaches, and outcome of acute renal failure in children. Curr Opin Pediatr 10:184–189Google Scholar
  9. 9.
    (2002) Treatment of adults and children with renal failure: standardised audit measures, 3rd edn. Renal Association, Royal College of Physicians, London, pp 137–143Google Scholar
  10. 10.
    Reznik VM, Randolph G, Collins CM, Peterson BM, Lemire JM, Mendoza SA (1993) Cost analysis of dialysis modalities for pediatric acute renal failure. Perit Dial Int 13:311–313PubMedGoogle Scholar
  11. 11.
    Baldwin I, Elderkin T, Bridge N (2002) Nursing management concepts for CRRT in the child. In: Bellomo R, Baldwin I, Ronco C, Golpe T (eds) Atlas of hemofiltration. Saunders, London, pp 83–95Google Scholar
  12. 12.
    Harvey B, Watson AR, Jepson S (2002) A renal critical care educator: the interface between paediatric intensive care and nephrology. Intensive Crit Care Nurs 18:250–254CrossRefPubMedGoogle Scholar
  13. 13.
    Warady BA, Bunchman T (2000) Dialysis therapy for children with acute renal failure: survey results. Pediatr Nephrol 15:11–13PubMedGoogle Scholar
  14. 14.
    Flynn JT, Kershaw DB, Smoyer WE, Brophy PD, McBryde KD, Bunchman E (2001) Peritoneal dialysis for management of pediatric acute renal failure. Perit Dial Int 21:390–394Google Scholar
  15. 15.
    Reznik VM, Griswold WR, Peterson BM, Rodarte A, Ferris ME, Mendoza SA (1997) Peritoneal dialysis for acute renal failure in children. Adv Ren Replace Ther 4 [Suppl 1]:93–101Google Scholar
  16. 16.
    Coulthard MG, Vernon B (1995) Managing acute renal failure in very low birthweight infants. Arch Dis Child 73:F187–F192Google Scholar
  17. 17.
    Lattouf OM, Ricketts RR (1986) Peritoneal dialysis in infants and children. Am Surg 52:66–69PubMedGoogle Scholar
  18. 18.
    Gouyon JB, Guignard JP (2000) Management of acute renal failure in newborns. Pediatr Nephrol 14:1037–1044CrossRefPubMedGoogle Scholar
  19. 19.
    Rainey KE, DiGeronimo RJ, Pascual-Baralt J (2000) Successful long-term peritoneal dialysis in a very low birth weight infant with renal failure secondary to feto-fetal transfusion syndrome. Pediatrics 106:849–851PubMedGoogle Scholar
  20. 20.
    Davenport A (1999) Is there a role for continuous renal replacement therapies in patients with liver and renal failure? Kidney Int 56 [Suppl 7]:S62–S66Google Scholar
  21. 21.
    Dittrich S, Vogel M, Dahnert I, Haas NA, Alexi-Meskishvili V, Lange PE (2000) Acute hemodynamic effects of post cardiotomy peritoneal dialysis in neonates and infants. Intensive Care Med 26:101–104PubMedGoogle Scholar
  22. 22.
    Daschner M, Schaefer F (2002) Emergency dialysis in neonatal metabolic crises. Adv Renal Replace Ther 9:63–69CrossRefGoogle Scholar
  23. 23.
    Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A (2002) Continuous venovenous hemodiafiltration in neonatal onset hyperammonemia. Am J Perinatol 19:221–224CrossRefPubMedGoogle Scholar
  24. 24.
    Summar M (2001) Current strategies for the management of neonatal urea cycle disorders (proceedings of a consensus conference for the management of patients with urea cycle disorders). J Pediatr 138:S30–S39CrossRefPubMedGoogle Scholar
  25. 25.
    Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E (1999) Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 14:910–918PubMedGoogle Scholar
  26. 26.
    Mattoo TK, Ahmad GS (1994) Peritoneal dialysis in neonates after major abdominal surgery. Am J Nephrol 14:6–8PubMedGoogle Scholar
  27. 27.
    Wong SN, Geary DF (1988) Comparison of temporary and permanent catheters for acute peritoneal dialysis. Arch Dis Child 63:827–831PubMedGoogle Scholar
  28. 28.
    Chadha V, Warady BA, Blowey DL, Simckes AM, Alon US (2000) Tenckhoff catheters prove superior to Cook catheters in pediatric acute peritoneal dialysis. Am J Kidney Dis 35:1111–1116PubMedGoogle Scholar
  29. 29.
    Huber R, Fuchshuber A, Huber P (1994) Acute peritoneal dialysis in preterm newborns and small infants: surgical management. J Pediatr Surg 29:400–422PubMedGoogle Scholar
  30. 30.
    Vande Walle J, Raes A, Castillo D, Lutz-Dettinger N, Dejaegher A (1997) New perspectives for PD in acute renal failure related to new catheter techniques and introduction of APD. Adv Perit Dial 13:190–194PubMedGoogle Scholar
  31. 31.
    Pumford N, Cassey J, Uttley WS (1994) Omentectomy with peritoneal catheter placement in acute renal failure. Nephron 68:327–328PubMedGoogle Scholar
  32. 32.
    Watson AR, Gartland C on behalf of the European Paediatric Peritoneal Dialysis Working Group (2001) Guidelines by an ad hoc European committee for elective chronic peritoneal dialysis in pediatric patients. Perit Dial Int 21:240–244PubMedGoogle Scholar
  33. 33.
    Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, Breborowicz A, Lindholm B (2001) Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 16:669–671CrossRefPubMedGoogle Scholar
  34. 34.
    Takahashi S, Shimada A, Okada K, Kuno T, Nagura Y, Hatano M (1991) Effect of intraperitoneal administration of heparin to patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 11:81–83PubMedGoogle Scholar
  35. 35.
    Zaramella P, Andreetta B, Zanon GF, Murer L, Montini G, Cantarutti F, Zacchello G (1994) Continuous peritoneal dialysis in newborns. Perit Dial Int 14:4–6PubMedGoogle Scholar
  36. 36.
    Valeri A, Radhakrishnan J, Vernocchi L, Carmichael LD, Stern L (1993) The epidemiology of peritonitis in acute peritoneal dialysis: a comparison between open- and closed-drainage systems. Am J Kidney Dis 21:300–309PubMedGoogle Scholar
  37. 37.
    Schroder CH on behalf of the European Paediatric Peritoneal Dialysis Working Group (2001) The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568–574PubMedGoogle Scholar
  38. 38.
    Kierdorf HP, Leue C, Arns S (1999) Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies. Kidney Int 56 [Suppl 7]:S36–S36Google Scholar
  39. 39.
    Vande Walle J, Raes A, Castillo D, Lutz-Dettinger N, Dejaegher A (1997) Advantages of HCO3 solution with low sodium concentration over standard lactate solutions for acute peritoneal dialysis. Adv Perit Dial 1:179–182Google Scholar
  40. 40.
    Fischbach M, Stefanidis CJ, Watson AR on behalf of the European Paediatric Peritoneal Dialysis Working Group (2002) Guidelines by an ad hoc European committee on adequacy of the paediatric peritoneal dialysis prescription. Nephrol Dial Transplant 17:380–385Google Scholar
  41. 41.
    Fischbach M, Terzic J, Laugel V, Escande B, Dangelser CI, Helmstetter A (2003) Measurement of IPP: a useful tool for the improvement of dialysis prescription. Pediatr Nephrol 10:976–980CrossRefGoogle Scholar
  42. 42.
    Holtta T, Ronnholm K, Holmberg C (2000) Adequacy of dialysis with tidal and continuous cycling peritoneal dialysis in children. Nephrol Dial Transplant 15:1438–1442CrossRefPubMedGoogle Scholar
  43. 43.
    Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Grontoft K-C, Larsson R, Bergland J, Tranaeus AP, Faict D (1998) Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 53:1061–1067CrossRefGoogle Scholar
  44. 44.
    Coleman JE, Edefonti A, Watson AR on behalf of the European Paediatric Peritoneal Dialysis Working Group (2001) Guidelines by an ad hoc European committee on the assessment of growth and nutritional status in children on chronic peritoneal dialysis. Perit Dial Int 21:333Google Scholar
  45. 45.
    Star RA (1998) Treatment of acute renal failure. Kidney Int 1817–1831Google Scholar
  46. 46.
    Lebland M, Ouimet D, Pichette V (2001) Dialysate leaks in peritoneal dialysis. Semin Dial 14:50–54CrossRefPubMedGoogle Scholar
  47. 47.
    Van de Kar NCAJ, Rusthoven E, Monnens LAH, Schroder CH (2001) Fibrin glue successfully used in peritoneal dialysis catheter leakage in children. Perit Dial Int 21 [Suppl 2]:163Google Scholar
  48. 48.
    Stadermann MB, Rusthoven E, Van de Kar NCA, Hendriksen A, Monnens LAH, Schroder CH (2002) Local fibrinolytic therapy with urokinase for peritoneal dialysis catheter obstruction. Perit Dial Int 22:84–86PubMedGoogle Scholar
  49. 49.
    Julian TB, Ribeiro U, Bruns F, Fraley D (1995) Malfunctioning peritoneal dialysis catheter repaired by laparoscopic surgery. Perit Dial Int 15:363–366PubMedGoogle Scholar
  50. 50.
    Warady BA on behalf of the International Society of Peritoneal Dialysis Advisory Committee on Peritonitis Management in Pediatric Patients (2000) Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 20:610–624Google Scholar
  51. 51.
    Goldstein SL, Currier H, Graf JM, Cosio CC, Brewer ED, Sachdeva R (2001) Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 107:1309–1312PubMedGoogle Scholar
  52. 52.
    McMaster P, Shann F (2003) The use of extracorporeal techniques to remove humoral factors in sepsis. Pediatr Crit Care Med 4:2–6CrossRefPubMedGoogle Scholar
  53. 53.
    Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N, Linde-Zwirble WT (2002) Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 28:29–37CrossRefGoogle Scholar
  54. 54.
    Ronco C, Bellomo R, Homel P, Brendolan A, Maurizio D, Piccinni P, La Greca G (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26–30PubMedGoogle Scholar
  55. 55.
    Castillo F, Nieto J, Salcedo S, Peguero G, Castello F (2000) Treatment of hydrops fetalis with hemofiltration. Pediatr Nephrol 15:14–16PubMedGoogle Scholar
  56. 56.
    Coulthard MG, Sharp J (1995) Haemodialysis and ultrafiltration in babies weighing under 1000 g. Arch Dis Child 73:F162–F165Google Scholar
  57. 57.
    Ponikvar R, Kandus A, Urbancic A, Kornhauser AG, Primozic J, Ponikvar JB (2002) Continuous renal replacement therapy and plasma exchange in newborns and infants. Artif Organs 26:163–168CrossRefPubMedGoogle Scholar
  58. 58.
    Clark WR, Ronco C (1999) CRRT efficiency and efficacy in relation to solute size. Kidney Int 57 [Suppl 72] S3–S7Google Scholar
  59. 59.
    Ronco C, Bellomo R, Kellum JA (2002) Continuous renal replacement therapy: opinion and evidence. Adv Renal Replace Ther 9:229–244CrossRefGoogle Scholar
  60. 60.
    Bellomo R, Ronco C (2002) An introduction to continuous renal replacement therapy. In: Bellomo R, Baldwin I, Ronco C, Golpe T (eds) Atlas of hemofiltration. Saunders, London, pp 1–9Google Scholar
  61. 61.
    Ellis EN, Pearson D, Belsha CW, Berry PL (1997) Use of pump-assisted hemofiltration in children with acute renal failure. Pediatr Nephrol 11:196–200PubMedGoogle Scholar
  62. 62.
    Baglin TP (2001) Heparin induced thrombocytopaenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 54:272–274CrossRefPubMedGoogle Scholar
  63. 63.
    Neuhaus TJ, Goetschel P, Schmugge M, Leumann E (2000) Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 14:713–716PubMedGoogle Scholar
  64. 64.
    Mehta RL, McDonald BR, Ward DM (1991) Regional citrate anticoagulation for continuous arteriovenous hemodialysis: an update after 12 months. Contrib Nephrol 93:210–214PubMedGoogle Scholar
  65. 65.
    Chadha V, Garg U, Warady BA, Alon US (2002) Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 17:819–824CrossRefPubMedGoogle Scholar
  66. 66.
    Wilkins B, Morrison A (2002) Pediatric CRRT. In: Bellomo R, Baldwin I, Ronco C, Golper T (eds) Atlas of hemofiltration. Saunders, London, pp 59–62Google Scholar
  67. 67.
    Brophy PD, Goldstein S, Bunchman TE (2002) Hemofiltration in children.
  68. 68.
    Mendley SR, Fine RN, Tejani A (2001) Dialysis in infants and children. In: Daugirdaus JT, Blake PG, Ing TS (eds) Handbook of dialysis, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 562–579Google Scholar
  69. 69.
    Paediatric nephrology nursing: guidance for nurses (2000) Royal College of Nursing, LondonGoogle Scholar
  70. 70.
    Harvey B, Watson AR (2003) Support for renal replacement therapy in the paediatric intensive care unit. Br J Renal Med (in press)Google Scholar
  71. 71.
    Subramanian S, Venkataraman R, Kellum JA (2002) Influence of dialysis membranes on outcomes in acute renal failure: a meta-analysis. Kidney Int 62:1819–1823CrossRefPubMedGoogle Scholar
  72. 72.
    Watson AR, Taylor CM, McGraw M (2003) Disorders of the urinary system In: McIntosh N, Helms PJ, Smyth RL (eds) Forfar and Arneil’s textbook of paediatrics, 6th edn. Churchill Livingstone, Edinburgh, pp 599–650Google Scholar
  73. 73.
    Burn R, Ashley C (eds) (1999) The renal drugs handbook. Radcliffe Medical Press, OxfordGoogle Scholar
  74. 74.
    (2002) Drug prescribing in patients on dialysis. In: Levy J, Morgan J, Brown E (eds) Oxford handbook of dialysis, vol 15. Oxford University Press, Oxford, pp 540–566Google Scholar

Copyright information

© IPNA 2004

Authors and Affiliations

  • Vladimirs Strazdins
    • 1
  • Alan R. Watson
    • 2
    Email author
  • Ben Harvey
    • 2
  1. 1.Nephrology DepartmentUniversity Hospital for ChildrenRigaLatvia
  2. 2.Children and Young People’s Kidney UnitNottingham City Hospital NHS TrustUK

Personalised recommendations